Henning Paul-Julius Stahlberg, Thomas Hofer, Wei Xu
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti-4-1BB antibodies, although effective preclinically, has not advanced to phase 3 trials because they hav ...
American Association for the Advancement of Science (AAAS)2019